C ongenital heart disease (CHD) is the most common developmental defect, occurring in almost 3% of neonates when including bicuspid aortic valve (BAV) patients. Numerous studies have shown that the overall incidence of CHD is relatively similar across populations (after accounting for the ascertainment bias associated with improved imaging over the past decades). The distribution of heart lesions is broadly similar with a few notable examples such as the relatively greater incidence of right-sided over leftsided defects among Asians (Sung et al. 1991; Pradat et al. 2003; Wu et al. 2010) .
The genetic architecture of CHD is incompletely understood. It has been long appreciated that chromosomal defects and single-gene disorders can cause CHD, often in the context of a multisystem disease. Common examples of aneuploidy with CHD would include trisomy 21, for which 50% of individuals will have atrioventricular canal defects and/or tetralogy of Fallot (TOF), and Turner syndrome (45,X), for which aortic coarctation is overrepresented. Examples of Mendelian disorders include autosomal dominant conditions with CHD and pleiomorphic extracardiac abnormalities such as Noonan and Holt-Oram syndromes and rare autosomal dominant isolated CHD such as caused by GATA4 and NKX2.5 mutations. The most common segmental aneuploidy is the 22q11 microdeletion, usually arising de novo, which accounts for a substantial 34% of truncus arteriosus and 16% of TOF (Goldmuntz et al. 1998) . Nonetheless, these known genetic causes of CHD are estimated to account for ,20% of CHD.
Epidemiologic studies strongly suggest genetic factors as the predominant cause of CHD, although environmental exposures are also relevant. The best population-based study of CHD was performed in Denmark, in which a nationwide medical registry enabled nearly complete ascertainment. In this study, the relative risk for any form of CHD in first-degree relatives was 3.2 (Oyen et al. 2009 ). The recurrence risks of the same form of CHD varied by lesion. After exclusion of chromosomal defects, the population-associated risk given a positive family history of CHD was 4.2%. Parental consanguinity is associated with a 2-to 3-fold increased offspring risk of CHD, likely because of the shared genetic variants among parents (Nabulsi et al. 2003; Yunis et al. 2006) . Finally, family studies of left-sided forms of CHD ranging from BAV to hypoplastic left heart syndrome have indicated a high degree of heritability (Cripe et al. 2004; McBride et al. 2005; Hinton et al. 2007 ).
In the 1960s, James Nora proposed a multifactorial model for CHD, in which polygenic inheritance combined with environmental factors would underlie cases not readily explained by aneuploidy, Mendelian genetic mutations, or teratogens (Nora 1968) . Although broadly popular for complex genetic traits, the multifactorial model has substantial problems when applied to CHD. Specifically, most of the predictions that flow from polygenic inheritance proved untrue for nearly all forms of CHD, patent ductus arteriosus in full-term newborns being the singular exception. In the 1980s, the groundbreaking work of Ruth Whittemore, who studied the progeny of women with CHD, further invalidated the multifactorial model (Whittemore et al. 1982) by documenting a 16% CHD recurrence rate, often with the same heart lesion, much greater than the 2% -3% rate expected for polygenic inheritance. Of interest, the recurrence risk for fathers with CHD is substantially lower. This sex-specific transmission risk remains largely unexplored.
In this article, we will review the role of genetic defects underlying CHD, focusing particularly on recent findings using relatively new genetic and genomic approaches.
MODIFIER GENES
Many monogenes or copy number variants (CNVs) associated with CHD are incompletely penetrant and/or phenotypically heterogeneous. Although complexity can result from nongenetic factors (environmental exposures/ epigenetics, stochastic effects), modifier genes are likely to be relevant. Recent efforts, particularly studies with animal models, have begun to address this latter possibility.
NKX2.5 mutations are associated with a range of lesions, including atrial septal defects, (ASDs), conotruncal defects, and hypoplastic left heart syndrome (HLHS), and often cause later-onset atrioventricular conduction block. Similarly, mice heterozygous for a null Nkx2.5 allele on a C57BL/6 background display a range of CHD, most commonly ASDs and ventricular septal defects (VSDs) (Winston et al. 2010) . F 1 offspring resulting from the outcrossing of C57BL/6 mice to FVB/N or AJ mice have significantly lower incidence of CHD. F 2 mice from F 1 intercrosses or N2 back-crosses to the parental strains have higher CHD rates (ASD 5% -12% and VSD 12% -15% vs. ASD 7% -8% and VSD 0% -1% in the F 1 pups). The analyses suggested the presence of genetic modifiers of Nkx2.5 on ASD and VSD phenotypes. Using a C57BL/ 6ÂFVB/N F 1 ÂF 1 intercross (Winston et al. 2012) , linkage analysis for membranous VSDs identified three loci with moderate-sized effects (odd ratios [ORs] of 1.4 to 2.2) (Fig. 1) . For muscular VSDs, there was no significant linkage, and two of the three loci for membranous VSDs were excluded. Of interest, a modest maternal age effect (OR ¼ 1.1) was also observed. Future work to identify the precise genetic alterations mediating these modifying effects in mice might be relevant to NKX2.5-related CHD in patients.
A similar strategy was used in mice heterozygous for a null elastin allele (Eln þ/2 ) (Kozel et al. 2011) . In humans, the ELN gene resides within the microdeletion associated with Williams syndrome. Haploinsufficiency for elastin is strongly implicated in the aortic pathology in Williams syndrome as individuals with ELN point mutations have the related, but more restricted phenotype, familial supraval-vular stenosis. Linkage analyses with intercrossed Eln þ/2 mice revealed three loci for aortic size and systemic hypertension. Of interest, one of the loci resides near the Eln locus, potentially affecting the Williams syndrome critical region.
A candidate gene resequencing approach of 26 genes in individuals with Down syndrome with either atrioventricular septal defects (AVSDs) or without CHD (Ackerman et al. 2012 ) identified potentially damaging variants in almost 20% of individuals with Down syndrome with AVSDs but in only 3% of those with Down syndrome without CHD. Six genes were specifically implicated: COL6A1, COL6A2, CRELD1, FBLN2, FRZB, and GATA5. Pathway analysis with these six genes implicated VEGF-A signaling, which was known to have a role in atrioventricular valvuloseptal morphogenesis. The findings in this study provide an initial proof of principal for using individuals with a sensitized genetic background like trisomy 21 that predisposes to CHD to explore additional genetic variants mediating expression of CHD phenotypes.
Further interesting insights into the genetic complexity of CHD were gained through mouse N-ethyl-N-nitrosourea (ENU) mutagenesis screens (Kamp et al. 2010 ). Three-generation backcrosses were conducted and lines with perinatal lethality were assessed for CHD. This breeding approach favors autosomal recessive mutations. The first CHD gene identified from these ENU screens was Ift172, which encodes an intraflagellar transport protein (Friedland-Little et al. 2011) . The mice with the Ift172 mutation showed a phenotype of VACTERL (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities) with hydrocephalus and CHD. Efforts to identify other genes are currently in progress. The interesting finding, particularly relevant here, is that 75% of the lines with CHD had only a single G 3 -affected pup, despite the assessment of at least 50 animals. Of note, control crosses in which the founders had not been exposed to ENU produced no third-generation offspring with CHD. Possible explanations for this finding include modifier genes because two of the three ENU screens were performed using mice with mixed genetic backgrounds, multigenic inheritance resulting from the ENU-induced mutational load, or fetal demise of some of the CHD-affected animals. Future studies, such as additional breeding to various mouse strains, would distinguish those possibilities and might facilitate identification of modifier genes when present.
DE NOVO MUTATIONS
Another form of genetic complexity is genetic lesions that arise de novo such that the parents do not harbor the mutation and family history is negative for CHD. For highly penetrant mutations underlying severe forms of CHD, this mechanism is more likely a result of low reproductive fitness because the modern era provides strong negative selection against the accumulation of these mutations in the population.
Through recent advances in molecular genetic technologies, it is now possible to sequence the 2% of the human genome that contains the coding regions for all genes (called the exome), representing 180,000 exons and 30 megabases (Mb), in a relatively rapid and affordable manner. Although exome sequencing was initially used to discover mutations underlying Mendelian disorders, current efforts are increasingly focusing on unraveling complex genetic traits.
The Pediatric Cardiac Genomics Consortium (PCGC) (Gelb et al. 2013 ), a National Heart, Lung, and Blood Institute -funded research collaborative, recently completed a firstof-a-kind study to determine the role of de novo mutations in the etiology of severe forms of CHD (Zaidi et al. 2013) . Exome sequencing was performed for 362 parent -offspring trios in which the offspring had a sporadic conotruncal defect, left ventricular outflow track obstructive lesion, or heterotaxy, and was compared with comparable data from 264 control trios.
Although the overall rate of de novo point and small insertion/deletion (indel) changes was equivalent between CHD cases and controls, there was an excess burden of protein-altering mutations in genes highly expressed in the heart during heart development (OR of 2.53). These excess mutations accounted for 10% of CHD cases and led to the estimate that approximately 400 genes underlie these cardiac lesions. After filtering to retain only variants most likely to be deleterious (nonsense, splice site, and frameshift defects), the burden among CHD cases increased, attaining an OR of 7.50.
Next, the PCGC investigators asked whether the burden of de novo protein-altering mutations among the CHD cases preferentially targeted particular biologic processes (Zaidi et al. 2013 ). Indeed, they observed a highly significant enrichment of mutations among genes encoding proteins relevant for chromatin biology, specifically the production, removal, or reading of methylation of Lys4 of histone 3 (H3K4me) (Fig. 2) . The phenotypes of the eight subjects harboring H3K4me de novo mutations was diverse, both with respect to the form of CHD and extracardiac manifestations. In addition, two independent de novo mutations were identified in SMAD2, which encodes a protein with relevance for demethylation of Lys27 of histone 3 (H3K27me). SMAD2 contributes to the development of the left -right body axis; both subjects harboring SMAD2 mutations had dextrocardia with unbalanced complete atrioventricular canal defects with pulmonic stenosis. Although the contribution of chromatin remodeling to cardiovascular development generally and to certain rare genetic syndromes with CHD like Kabuki syndrome had been recognized previously, this study exposed a far broader role for H3K4 methylation in CHD pathogenesis. The finding also suggests a fascinating potential link to other birth defects as de novo chromatin-remodeling mutations have also been implicated in autism (O'Roak et al. 2012) .
COPY NUMBER VARIATION
Copy number variation (CNV), or gains or losses of contiguous DNA ranging in size from B.D. Gelb and W.K. Chung 1 kb to several Mbs, affects 10% of the human genome (Redon et al. 2006) . CNVs are typically detected on a genome-wide basis using singlenucleotide polymorphism (SNP) microarrays or array comparative genomic hybridization. Significant challenges remain in differentiating pathologic CNVs from benign polymorphic ones. Nevertheless, it became clear soon after their discovery that pathologic CNVs contribute significantly to the pathogenesis of certain phenotypes such as autism and schizophrenia. Thienpont and colleagues (2007) showed the importance of pathologic CNVs for CHD. The studies published to date have often focused on particular subpopulations of individuals with CHD, often based on cardiac anatomy. Certain CNVs are recurrent and at higher frequency in individuals with CHD, often ones that are also associated with extracardiac abnormalities.
The role of CNVs for TOF has been studied in two large studies. In one, 10% of 114 patients with TOF were found to harbor rare de novo CNVs (Greenway et al. 2009 ). Next, nearly 400 probands with TOF were assessed for CNVs at nine genomic loci and were identified in 5%. Several CNVs were recurrent with both gain and loss at chromosome 1q21.1 being observed in 1% of cases. Of note, 1q21.1 CNVs have previously been associated with other phenotypes such as autism, schizophrenia, and intellectual disabilities.
In the second large study of TOF, more than 400 adults with TOF with or without pulmonary atresia, but without known genetic abnormalities like the 22q11 deletion, were studied (Silversides et al. 2012 ). Large, rare CNVs (.500 kb) were more prevalent in cases compared with controls (8.8% vs. 4.3%) with mostly genomic gains. Especially when the CNVs contained genes, the subjects were more likely to have extracardiac abnormalities. Several of the CNVs had been previously implicated in diseases including duplications at 1q21.1, which were observed in 1.2% of CHD patients, a 16p11.2 duplication, and a 22q11.21 duplication.
Two studies focused on CNVs in individuals with defects of the left ventricular outflow tract (Hitz et al. 2012; Payne et al. 2012) . In a small study of children with HLHS, CNVs, predominantly small lesions, were more common among subjects than controls (Payne et al. 2012) . The frequency of rare CNVs, however, did not vary between the groups. In a study that included individuals with a broad range of left-sided cardiac lesions with a focus on those from families with more than one affected individual, the overall burden of CNVs was not increased in cases over controls, but a number of rare CNVs were identified in cases only, none of which was recurrent in the study (Hitz et al. 2012) . Of interest, these rare CNVs were found to harbor genes relevant for angiogenesis. After filtering, the investigators identified 25 putative candidate genes for left-sided heart defects.
The role of CNVs in AVSDs, both in patients with and without Down syndrome, was investigated (Priest et al. 2012 (Fakhro et al. 2011) . More than 250 patients with heterotaxy and nearly 1000 controls were genotyped with SNP arrays. There were nearly twofold more rare CNVs among the heterotaxy cohort compared with the controls (14.5% vs. 7.4%, respectively). In the 38 smaller CNVs identified, 14 of 61 genes altered were relevant to biological processes of relevance for leftright axis development: ciliary function, zinc finger transcription factors, and TGF-b signaling. Five genes contained within CNVareas were shown to be significant by examining conserved genes located within these intervals and functionally evaluating the effect of knockdown of these genes in the frog Xenopus tropicalis. Specifically, knockdown of NEK2, ROCK2, TCGBR2, GALNT11, and NUP188 disrupted left -right development (Fig. 3) ; none had been previously implicated in left -right patterning.
A genome-wide CNV study of various types of CHD compared more than 2000 CHD cases including approximately 800 with TOF to nearly 900 controls (Soemedi et al. 2012b ). They found a significant burden of rare loss CNVs .100 kb containing genes (OR 1.8; population-attributable risk of nearly 3.5%). There was a trend toward greater ORs with increasing CNV deletion size and gene content. Enrichment analysis with the rare loss CNVs revealed a significant association with WNT signaling, which was altered in a broad range of CHD. Examining CNVs that were recurrent, the investigators confirmed prior observations of gain and loss CNVs including GATA4 at 8p23.1 and deletions at 15q11.2 in 0.5% of cases, an OR of 8.2 compared with controls. Finally, the parent of origin for de novo CNVs was assessed in 11 cases, of which 10 were paternal.
Restricting the search for CNVs to genes previously implicated in CHD, another study compared more than 800 CHD cases without known genomic defects (e.g., Down syndrome, 22q11del) to 3000 controls (Tomita-Mitchell et al. 2012 ). Large, rare CNVs (.100 kb for losses and .200 kb for gains) were observed in 4.3% of cases compared with 1.8% of controls, a significant difference. The previously noted gain at 1q21.1 and loss at 8p23.1 that includes GATA4 were detected in this study as well. Of interest, two CHD subjects without a clear syndrome were found to harbor gains of HRAS, the gene with gain-of-function mutations underlying Costello syndrome.
The role of 1q21.1 CNVs in CHD was investigated in a mixed CHD population, although enriched for TOF (Soemedi et al. 2012a) . Gain CNVs were observed in 8/948 cases compared with 3/10,910 controls, an OR of 30.9. Smaller gain CNVs (100 -200 kb) including GJA5 were also increased among the TOF cases with an OR of 10.7. Although no 1q21.1 losses were identified in this TOF cohort, three losses (but no gains) were observed among nearly 1500 cases of assorted other forms of CHD. Taken as a whole, this study suggested that 1q21.1 gains account for 1% of TOF, possibly a result of altered expression of GJA5.
COMMON VARIANTS
To examine the possibility that common genetic variants contribute to the etiology of CHD, two groups have recently completed genome-wide association studies (GWASs). A GWAS including nearly 1000 Han Chinese with ASD and/or VSD and more than 1200 racially matched controls in the discovery group and (Hu et al. 2013) nearly 1600 ASD/VSD subjects and 2300 controls in the replication cohort identified two SNPs, at 1p12 and 4q31.1 that were replicated in the second stage as well as within an additional second replication cohort (582 cases and 1565 controls). In aggregate, the associations of these two SNPs with CHD were highly significant (P , 1 Â 10 29 and 5 Â 10 212 , respectively) and both had ORs of 1.4 (Fig. 4) . For the 1p12 locus, the nearest relevant gene is TBX15, which encodes a T-box transcription factor. Although mutations in several TBX genes cause CHD in humans and mice, loss of Tbx15 in mice is not associated with heart abnormalities and no TBX15 mutation has been found in a human. The gene MAML3, which encodes mastermind-like 3, resides in the 4q31.1 locus. Mastermind proteins bind Notch, a key devel- opmental regulator, and have transcription activation domains. Loss of Maml3 in mice is not associated with an observable phenotype, and no human MAML3 mutation has been identified to date. Finally, this GWAS did not confirm associations with any of the previously published SNPs. It is not clear whether the failure to replicate is attributable to prior published false positives, as most of the previously published studies were based on modest-sized cohorts, or to differences in race and ethnicity of the subjects.
A GWAS of more than 1800 European Caucasians with various forms of CHD with more than 5100 controls failed to identify any SNPs with genome-wide significance (Cordell et al. 2013a) . Subgroup analyses based on CHD anatomy produced suggestive P values for ASD and VSD. Replication cohorts (more than 400 ASD and 200 VSD cases compared with more than 2500 controls) genotyped for 10 SNPs from six regions showed association of ASD to a locus at chromosome 4p16 (combined P , 3 Â 10 210 and OR of 1.5). Within this region, the best candidate gene was MSX1, which encodes a transcription factor relevant for atrial septal development. Loss-of-function MSX1 mutations in humans alter craniofacial and dental development, but have not been associated with CHD.
In a separate GWAS publication, this group studied 800 cases of TOF and more than 5100 controls in the discovery phase and 800 cases and 3000 controls for replication (Cordell et al. 2013b ) and identified two regions of interest at 12q24 (P , 8 Â 10 211 ; OR 1.3) and 13q32 (P ¼ 3.0 Â 10 211 ; OR 1.3). The 12q24 locus has been implicated in GWASs for other complex genetic traits such as type 1 diabetes and coronary artery disease, but no other developmental disorder. The best candidate gene at 12q24 is PTPN11, which encodes SHP-2, a protein tyrosine phosphatase. PTPN11 mutations cause Noonan and LEOPARD syndromes, which can include pulmonary valve stenosis. The best candidate gene from the 13q32 locus is GPC5, which encodes the heparan sulphate proteoglycan glypican 5. Glypicans serve as regulators of signaling pathways during development, and mutations in genes for other glypican family members are associated with CHD.
Of interest, both major CHD GWAS studies identified associations for ASDs, albeit different loci. Because this heart lesion would seem to have the smallest effect on reproductive fitness, common variants not subject to strong purifying selection is more likely than for other lesions. Future work will need to confirm these findings and then establish the biological effects of the relevant common variant in the region.
NONCODING MUTATIONS
Mutations in gene promoters, enhancers, locus control regions, microRNAs, and even intergenic regions are likely to be relevant for CHD causality. Although ongoing large-scale genomics efforts such as ENCODE are facilitating such work (Dunham et al. 2012) , the task of identifying disease-causing variation in noncoding regions of the human genome remains daunting.
A recent study focused on the identification of cis-regulatory elements for TBX5, the gene mutated in Holt-Oram syndrome (Smemo et al. 2012) . Using a series of constructs with LacZ reporters in transgenic mice, a 700-kb region around TBX5 was scanned and three enhancer elements residing 380 kb, 140 kb, and 9 kb downstream of TBX5 that drove cardiac expression were identified (Fig. 5) . The three enhancer regions were sequenced in 260 unrelated individuals with ASDs, VSDs, or AVSDs. Among the nine rare or novel variants identified, one altering a highly conserved nucleotide was homozygous for the variant allele in a subject with a VSD. When tested in vitro, the oligonucleotide with the variant bound the transcription factor less avidly. Strikingly, use of the variant sequence with reporters in transgenic mice or zebrafish embryos resulted in dramatically reduced expression in the heart. Thus, the investigators provided strong evidence that this single nucleotide variant in a TBX5 enhancer alters expression of the gene during heart development. The challenges, well illuminated through this study, are how to prove causality definitively and how to scale such work as large numbers of candidate variants are identified through wholegenome sequencing.
CONCLUDING REMARKS
Since the earliest ideas about the genetics of CHD as a complex trait were proposed 35 years ago, substantial progress has been made in understanding that complexity. Following an era of gene discovery based on highly penetrant mutations with Mendelian segregation with CHD, we have now entered an exciting period in which the landscape of the genetic complexity is being explored robustly. This has been enabled by advances in genotyping and sequencing technology and new methods for detecting CNVs. The most recent large-scale efforts to understand the noncoding portions of the human genome, particularly through ENCODE (Dunham et al. 2012) , will allow CHD researchers to expand their search for causative variation.
As exemplified by the finding that de novo mutations underlying CHD often alter chromatin remodeling, epigenetic modifications are probably important for CHD pathogenesis. Because epigenetic states can be tissue-specific, efforts to procure and study cardiac tissues will be needed. Moreover, these discoveries underscore the likelihood that interactions of genetic variation with environmental exposures will prove relevant for understanding the complexity of CHD. Research methodologies for addressing geneÂenvironment interactions are still emerging and may require international ef- forts to assemble CHD cohorts of sufficient size to power studies. Finally, researchers and physicians caring for individuals with CHD and their families will need to creatively and cooperatively translate genetic findings into meaningful medical advances. Low-hanging fruit is likely to include better prediction of recurrence risks for couples with a prior child with CHD and offspring risk for adults with CHD as well as improved prognostication of extracardiac involvement for infants with CHD. More challenging, but potentially more impactful, would be the development of therapies to reduce its incidence.
